Volume 5.03 | Jan 24

Cord Blood News 5.03 January 24, 2013
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter

Neurodevelopmental Outcomes of Umbilical Cord Blood Transplantation in Metachromatic Leukodystrophy
Investigators evaluated long-term treatment outcomes after unrelated donor umbilical cord blood transplantation in pediatric patients according to disease burden and age at onset. [Biol Blood Marrow Transplant] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells

PUBLICATIONS (Ranked by impact factor of the journal)

Apolipoprotein(a) Inhibits In Vitro Tube Formation in Endothelial Cells: Identification of Roles for Kringle V and the Plasminogen Activation System
Scientists evaluated the ability of apolipoprotein(a) to inhibit VEGF- and angiopoietin-induced tube formation in human umbilical cord endothelial cells. [PLoS One] Full Article

Multiple Unit Pooled Umbilical Cord Blood Is a Viable Source of Therapeutic Regulatory T Cells
Umbilical cord blood (UCB) offers certain advantages over adult peripheral blood (APB) as a source of regulatory T cells (Treg) for cellular therapy but yields far fewer Treg per unit. Pooling of Treg from multiple donors may overcome this challenge. Researchers assessed the in vitro and in vivo efficacy of multiple donor pooled UCB or APB-derived Treg. [Transplantation] Abstract

Pre-Engraftment Syndrome after Myeloablative Dual Umbilical Cord Blood Transplantation: Risk Factors and Response to Treatment
The incidence of acute GvHD or treatment-related mortality was not influenced by the choice to use corticosteroids to treat pre-engraftment syndrome (PES). This study suggests that use of CYA for GvHD prophylaxis increases the risk of PES following dual umbilical cord blood transplantation. [Bone Marrow Transplant] Abstract

The Role of Human Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells (UCX(R)) in the Treatment of Inflammatory Arthritis
Investigators report the immunosuppressive capacity of UCX(R) cells for treating induced autoimmune inflammatory arthritis. [J Transl Med] Abstract | Full Article

The Mitigating Effects of hUCB-MSCs on the Hematopoietic Syndrome Resulting from Total Body Irradiation
Researchers evaluated the clinical and pathological effects of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in the recovery from total body irradiation by comparing with the effects of granulocyte-colony stimulating factor, an efficacious drug in the treatment of acute bone marrow radiation syndrome. [Exp Hematol] Abstract

Human Herpesvirus-6 Encephalitis during Hematopoietic Stem Cell Transplantation Leads to Poor Prognosis
The authors analyzed risk factors for symptomatic human herpesvirus-6 (HHV-6) reactivation and the development of HHV-6 encephalitis in 140 consecutive adult patients who received allogeneic hematopoietic stem cell transplantation at their institution. Stem cell sources for the recipients were as follows: related-donor bone marrow in 40, related-donor peripheral blood in 5, unrelated bone marrow in 67, and unrelated cord blood in 28. [Transplant Infect Dis] Abstract

Chondrogenic Differentiation of Umbilical Cord-Derived Mesenchymal Stem Cells in Type I Collagen-Hydrogel for Cartilage Engineering
Researchers aimed to determine the potential of human umbilical cord-derived mesenchymal stem cells in cartilage healing. [Injury] Abstract

Human Umbilical Cord Blood Mononuclear Cell Conditioned Media Inhibits Hypoxic-Induced Apoptosis in Human Coronary Artery Endothelial Cells and Cardiac Myocytes by Activation of the Survival Protein Akt
Scientists hypothesized that the beneficial effects of human umbilical cord blood mononuclear cells (HUCBCs) are due to secretion of biologically active factors that activate in cardiac endothelial cells and myocytes the cell survival protein Akt. They concluded that HUCBCs secrete biologically active factors during hypoxia that activate survival proteins in endothelial cells and myocytes that significantly limit apoptosis. [Cell Transplant] Abstract

StemSpan ACF: The WORLD'S FIRST Plasma Component-Free Hematopoietic Expansion Medium. Come learn more.


Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
Kiadis Pharma B.V. announced that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product ATIR™. ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors. [Kiadis Pharma B.V.] Press Release

Northwestern Medicine Plans $1 Billion Research Investment
Leaders of Northwestern Medicine, comprising Northwestern University Feinberg School of Medicine, Northwestern Medical Faculty Foundation and Northwestern Memorial HealthCare, announced they have made a transformational commitment of more than $1 billion toward creating a leading medical research enterprise on Northwestern’s campus in Chicago’s Streeterville neighborhood. [Northwestern University] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW American Society of Gene & Cell Therapy (ASGCT) 16th Annual Meeting 2013
May 15-18, 2013
Salt Lake City, United States

NEW International Society for Stem Cell Research (ISSCR) 11th Annual Meeting
June 12-15, 2013
Boston, United States

View our events page to see a complete list of events in the cord blood community.


Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position (University of Iowa College of Medicine)

Postdoctoral Research Associate (Washington University in St Louis – School Of Medicine)

Postdoctoral Research Scientist (Anthony Nolan/University College London)

Postdoctoral Fellow (University of Michigan – Ann Arbor)

Postdoctoral Fellow (Mount Sinai Medical Center)

Early Stage Researcher PhD Posts – DECIDE ITN (The University of Birmingham)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us